Zoetis Inc. (NYSE:ZTS) Shares Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 72.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 93,114 shares of the company’s stock after purchasing an additional 39,114 shares during the period. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $15,171,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ZTS. AMF Tjanstepension AB grew its holdings in Zoetis by 23.4% during the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after acquiring an additional 20,001 shares during the period. Howard Capital Management Group LLC grew its holdings in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after acquiring an additional 883 shares during the period. Pallas Capital Advisors LLC grew its holdings in Zoetis by 6.0% during the third quarter. Pallas Capital Advisors LLC now owns 7,934 shares of the company’s stock worth $1,440,000 after acquiring an additional 451 shares during the period. Traynor Capital Management Inc. acquired a new position in Zoetis during the third quarter worth about $201,000. Finally, Fortitude Family Office LLC grew its holdings in Zoetis by 1,387.5% during the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Zoetis Trading Down 2.1 %

Shares of NYSE ZTS opened at $164.99 on Thursday. The firm has a market capitalization of $73.88 billion, a PE ratio of 30.16, a PEG ratio of 2.78 and a beta of 0.90. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The business has a 50-day moving average price of $166.22 and a two-hundred day moving average price of $177.58.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ZTS. UBS Group started coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $215.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.